Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2027

Conditions

Breast Cancer MetastaticBreast Cancer Brain Metastases

Interventions

DRUG

SHR-A1811

ADC

DRUG

Bevacizumab

bevacizumab biosimilar

DRUG

Pyrotinib

anti-HER2 inhibitor

Trial Locations (1)

RECRUITING

Fudan Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER